中华皮肤科杂志 ›› 2013, Vol. 46 ›› Issue (5): 328-331.

• 论著 • 上一篇    下一篇

淋球菌重组腺病毒在小鼠体内的免疫效果研究

陆原1,廉翠红2   

  1. 1. 深圳市第六人民医院
    2. 深圳市第二人民医院
  • 收稿日期:2012-03-06 修回日期:2013-02-04 出版日期:2013-05-15 发布日期:2013-05-01
  • 通讯作者: 廉翠红 E-mail:15814692161@163.com

Immunogenicity evaluation of a recombinant adenovirus containing the PIB and NspA genes of Neisseria gonorrhoeae in mice

Yuan LU,Cui-Hong LIAN   

  • Received:2012-03-06 Revised:2013-02-04 Online:2013-05-15 Published:2013-05-01
  • Contact: Cui-Hong LIAN E-mail:15814692161@163.com

摘要: 【摘要】 目的 探讨含有淋球菌PIB(Porin IB)与NspA(Neisseria surface protein A)基因的重组腺病毒在BALB/c小鼠体内的免疫效果。 方法 将30只雌性BALB/c小鼠随机分为5组,即重组腺病毒pAdEasy-1-PN低、中、高剂量组, pAdEasy-1对照组和空白对照组,在第0周和第4周以肌内注射方式免疫BALB/c小鼠两次,低、中、高组的免疫剂量分别为每只每次104、106、108组织细胞半数感染量(TCID50)。在免疫开始的第0、3、5周收集血清,并于第5周无菌取脾脏,分离淋巴细胞,采用酶联免疫吸附试验(ELISA)分别检测血清中特异性PIB抗体水平和特异性NspA抗体水平,采用噻唑蓝(MTT)法检测特异性淋巴细胞增殖活性,采用玻片凝集试验和补体溶菌试验检测免疫小鼠血清的抗菌活性。应用t检验处理实验数据。结果 在重组腺病毒免疫后的小鼠中均可检测出针对PIB抗原和NspA抗原的特异性细胞免疫反应和体液免疫反应。在免疫后的第3周和第5周,PIB抗体水平(F值分别为285.72和564.83,均P < 0.01)和NspA抗体水平(F值分别为521.57和542.61,均P < 0.01)在不同组别差异均有统计学意义。PIB和NspA特异性淋巴细胞刺激指数在不同组别中差异也存在统计学意义(F值分别为171.61和233.96,P < 0.01)。免疫效果与免疫剂量呈正相关,108TCID50/(次·只)是较为合适的免疫剂量。免疫小鼠血清可凝集淋球菌,并可在补体参与下将其杀灭。结论含有淋球菌PIB与NspA基因的重组腺病毒可在BALB/c小鼠体内产生特异性细胞免疫反应和体液免疫反应,是潜在的淋球菌疫苗。 【关键词】 奈瑟球菌,淋病; 腺病毒科; 疫苗,DNA

关键词: 奈瑟球菌,淋病, 腺病毒科, 疫苗,DNA

Abstract: LU Yuan *, LIAN Cui-hong. *Department of Dermatology, Nanshan Hospital Affiliated to Guangdong Medical College, Shenzhen 518052, China Corresponding author: LIAN Cui-hong, Email: cuihong_lian@yahoo.com.cn 【Abstract】 Objective To evaluate the immunogenicity of a recombinant adenovirus containing the porin IB (PIB) gene and Neisseria surface protein A (NspA) gene of N. gonorrhoeae in BALB/c mice. Methods A recombinant adenovirus containing the PIB gene and NspA gene of N. gonorrhoeae (pAdEasy-1-PN) was constructed in previous studies. Thirty BALB/c mice were randomly and equally divided into 5 groups: low-, medium- and high-dose experiment group intramuscularly immunized with 104, 106, and 108 50% tissue culture infective dose (TCID50) of the recombinant adenovirus pAdEasy-1-PN, respectively, pAdEasy-1 control group immunized with 106 TCID50 of pAdEasy-1, blank control group immunized with sodium chloride physiological solution. Immunization was carried out twice at a 4-week interval. Serum samples were collected at 0, 3 and 5 weeks after the first immunization, and spleens were removed at 5 weeks followed by the isolation of spleen lymphocytes. Enzyme linked immunosorbent assay (ELISA) was performed to determine the serum levels of PIB-specific and NspA-specific antibodies, methyl thiazolyl tetrazolium (MTT) assay to evaluate the proliferaton activity of spleen lymphocytes after stimulation by the recombinant PIB and NspA antigens. A slide agglutination test was used to estimate the anti-bacterial activity of murine serum. The complement-dependent bacteriolytic activity of murine serum was also evaluated. Statistical analysis was carried out by t test. Results Both humoral and cellular immune response specific to PIB and NspA were elicited by the recombinant adenovirus in mice. At 3 and 5 weeks after the immunization, significant differences were observed in the serum levels of PIB-specific (F = 285.72, 564.83, respectively, both P < 0.01) and NspA-specific (F = 521.57, 542.61, respectively, both P < 0.01) antibodies. Also, the proliferation index was statistically different among these groups in spleen lymphocytes stimulated with PIB and NspA (F = 171.61, 233.96, respectively, both P < 0.01). The vaccination efficiency was positively correlated with the inoculation dose of recombinant pAdEasy-1-PN, and 108 TCID50 per dose proved to be the optimal dose for immunization. The sera from mice immunized with pAdEasy-1-PN could agglutinate N. gonorrhoeae and kill it in the presence of complement. Conclusions The recombinant adenovirus pAdEasy-1-PN containing PIB and NspA genes could induce specific humoral and cellular immune response in mice, and may be a potential vaccine against N. gonorrhoeae. 【Key words】 Neisseria gonorrhoeae; Adenoviridae; Vaccines, DNA